- Report
- March 2025
- 187 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- August 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- March 2025
- 266 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- May 2024
- 181 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- March 2025
United Kingdom
From €3808EUR$3,990USD£3,191GBP
- Report
- February 2024
- 75 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- June 2023
- 135 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2024
- 132 Pages
Global
From €907EUR$950USD£760GBP
- Report
- October 2023
- 306 Pages
Global
From €3407EUR$3,570USD£2,855GBP
- Book
- October 2019
- 720 Pages

Erythromycins are a class of antibiotics used to treat a wide range of bacterial infections. They are derived from the bacterium Saccharopolyspora erythraea and are effective against Gram-positive bacteria, including Streptococcus, Staphylococcus, and Corynebacterium species. Erythromycins are also used to treat some Gram-negative bacteria, such as Haemophilus influenzae and Neisseria gonorrhoeae. They are available in various forms, including tablets, capsules, suspensions, and injections.
Erythromycins are generally well-tolerated and have fewer side effects than other antibiotics. However, they can cause gastrointestinal upset, including nausea, vomiting, and diarrhea. They can also interact with other medications, so it is important to discuss any potential interactions with a healthcare provider before taking them.
Some companies that produce erythromycins include Pfizer, Merck, GlaxoSmithKline, and AstraZeneca. Show Less Read more